title: Clinical protocol. Intra-Lesional rF-B7.1 versus rF-TRICOM vaccine in the treatment of metastatic cancer.
authors.affiliation: Department of Surgery, Columbia Presbyterian Medical Center, New York, NY 10032, USA. hlk2003@columbia.edu
authors.forename: Howard L
authors.initials: HL
authors.lastname: Kaufman
authors.forename: Kenneth
authors.initials: K
authors.lastname: Cheung
authors.forename: Ziv
authors.initials: Z
authors.lastname: Haskall
authors.forename: Heidi
authors.initials: H
authors.lastname: Horig
authors.forename: Charles
authors.initials: C
authors.lastname: Hesdorffer
authors.forename: Dennis
authors.initials: D
authors.lastname: Panicali
authors.forename: Gail
authors.initials: G
authors.lastname: DeRaffele
authors.forename: Kathryn
authors.initials: K
authors.lastname: Spanknebel
mesh_terms: D000328:Adult; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D002985:Clinical Protocols; D032962:Consent Forms; D004339:Drug Compounding; D006801:Humans; D015552:Injections, Intralesional; D009362:Neoplasm Metastasis / Q000276:immunology / Q000628:therapy*; D018579:Patient Selection; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000235:genetics / Q000627:therapeutic use*
chemical_list: D019496:Cancer Vaccines; D014614:Vaccines, Synthetic; C479601:rF-B7.1 vaccine; C479602:rF-TRICOM vaccine